Clinical Trials · NCT01923181
Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 632
- Start date
- Dec 2013
- Locations
- 103 sites, 14 countries
- Primary endpoint
- Change in HbA1c (Glycosylated Haemoglobin)